News

Bayer has launched a Phase 4 clinical trial called REPLACE to evaluate Adempas (riociguat) in patients with pulmonary arterial hypertension (PAH) who do not respond properly to treatment with certain inhibitors such as Revatio (sildenafil) or Adcirca (tadalafil). The study is also sponsored by Merck, and is expected to enroll…

Pulmonary hypertension (PH) in patients with chronic obstructive pulmonary disease (COPD) was associated with higher mortality rates after bilateral lung transplantation (transplantation of both lungs), but not after single lung transplantation (LTx), according to a new study of the United Network for Organ Sharing (UNOS) database. The study, “…

The lung functioning of pulmonary hypertension patients treated with Bayer’s Adempas improved by 50 percent over a median of six years and stabilized in another 45 percent, according to a Phase 2 clinical trial. Those findings and others indicate that Adempas is a good long-term therapy for pulmonary…

High blood pressure in the right artery makes a person with pulmonary arterial hypertension almost 2 1/2 times more likely to die than a patient with lower pressure, according to a study focusing on how doctors can use echocardiograms to predict poor PAH prognosis. Other echocardiogram measurements that can signal poor outcome…

Adverse drug events (ADEs) associated with subcutaneous treprostinil use for the treatment of pulmonary arterial hypertension (PAH) were found not to be associated with a higher mortality risk, except for ADEs involving gastrointestinal side effects, which may indicate that the PAH patient population can be divided into subgroups that respond differently…

Icagen and Omdana Therapeutics are teaming up to develop treatments for pulmonary hypertension (PH) and other vascular remodeling diseases, and tissue disorders. At the heart of the collaboration will be a joint treatment discovery team. Omdana develops treatments for PH, whose hallmark is high blood pressure in the lung’s blood…

Johnson & Johnson has completed its acquisition of Actelion, a company that develops pulmonary hypertension therapies, six months after the deal was announced in January. Actelion is now part of J&J’s Janssen Pharmaceuticals subsidiary, according to a news release. Janssen pledged to maintain the leadership position that Actelion built in…

A new Pulmonary Hypertension Association awareness campaign is featuring singer Traci Braxton, who has two sisters with related diseases. The public service ads, an extension of a previous awareness effort, are in print, online, and on radio and television. One target will be commuters going in and out of Amtrak’s Northeast…

https://www.youtube.com/watch?v=ie774xv413A   In this video from GSK, the chairman of the Pulmonary Hypertension Association in the U.K., Iain Armstrong, talks about what pulmonary hypertension (PH) is and how it affects those living with the disease. MORE: Can pulmonary hypertension be prevented? Armstrong explains that the disease affects…

Balloon pulmonary angioplasty, a procedure to widen narrowed lung blood vessels, was still benefitting patients with chronic thromboembolic pulmonary hypertension (CTEPH) six months after doctors performed it, a Japanese study found. The procedure increased patients’ cardiac output, or amount of the blood the heart is pumping, and exercise capacity, researchers said.

Stacie is a 27-year-old who loves the outdoors. Her journey with pulmonary hypertension began when she was an infant: at just 10 months old, she had double pneumonia. Although she recovered, she became sick again a month later. After visiting an on-call doctor who happened to be a heart specialist, her family…

A subcutaneous infusion of Remodulin (treprostinil) was an effective and tolerable treatment against severe pulmonary hypertension associated with chronic kidney disease in a patient on hemodialysis, according to a case report. The case study “Subcutaneous treprostinil was effective and tolerable in a patient with severe pulmonary hypertension associated with…